Supernus Pharmaceuticals (SUPN) has risen sharply, recording gains of 5.23% in the past 4 weeks. However, the stock has corrected -2.43% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 4.83% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
Supernus Pharmaceuticals, Inc. is up 23.15% in the last 3-month period. Year-to-Date the stock performance stands at 64.66%. The stock has recorded a 20-day Moving Average of 1.18% and the 50-Day Moving Average is 5.79%.
Supernus Pharmaceuticals (NASDAQ:SUPN): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $22.09 and $21.88 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $22.68. The buying momentum continued till the end and the stock did not give up its gains. It closed at $22.13, notching a gain of 0.18% for the day. The total traded volume was 689,084 . The stock had closed at $22.09 on the previous day.
Also, Equity Analysts at the Jefferies maintains the rating on Supernus Pharmaceuticals (NASDAQ:SUPN). The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency raises the price target from $23 per share to $28 per share. The rating by the firm was issued on August 4, 2016.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder), and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR, Trokendi XR, SPN-810, SPN-812 and SPN-809.